Webinar: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises
A BioSpace webinar highlighted how biotech firms can close the expectation gap with the FDA to avoid last‑minute decision‑day setbacks. Speakers emphasized the FDA’s recent pledge—led by Commissioner Marty Makary and CBER Director Vinay Prasad—to provide regulatory navigation for small companies, especially those targeting rare pediatric diseases. The discussion showcased practical tools such as AI‑driven review platforms and in‑silico modeling to secure accelerated pathways. Panelists from the Rare Disease Company Coalition, GATC Health, Capricor Therapeutics, and CervoMed shared real‑world strategies for aligning on endpoints and communication.
Leadership, Not Managers, More Likely To Drive Employees Away, BioSpace Finds
A BioSpace survey of U.S. life‑science professionals shows 15% are looking for new jobs because they are unhappy with company leadership, compared with 9.1% citing dissatisfaction with their direct manager. Respect for CEOs remains flat at roughly 80%, while respect...
Beyond the Cornfields, Indiana’s Life Sciences Industry Grows Tall
Indiana’s life‑sciences sector is rapidly expanding, now encompassing over 3,300 companies that employ roughly 70,000 workers and generate a $102 billion economic impact. Flagship firms such as Eli Lilly are driving major investments, including a $13 billion Medicine Foundry slated to create 400...
UCB Investing $2B To Build Manufacturing Facility in Georgia
UCB announced a $2 billion investment to build a 460,000‑square‑foot biologics manufacturing plant in Gwinnett County, Georgia, its first U.S. production site. The facility will create about 330 permanent jobs and over 1,000 construction positions, leveraging AI, robotics and automation. Georgia...
11 Companies Hiring Now in New York
New York’s life‑sciences cluster, anchored by pharma giants such as AbbVie, Merck, Pfizer and a suite of top universities, is experiencing a hiring surge. BioSpace data show job postings in February rose 22% year‑over‑year and 13% month‑over‑month, with roughly 300 positions...
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq
RA Capital Management has filed a prospectus for a new SPAC, Research Alliance III, with up to $57.5 million of capital. The blank‑check vehicle is openly scouting life‑science startups, emphasizing Chinese drug developers as potential targets. While the SPAC has not yet...
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Gilead announced a $2.1 billion acquisition of Ouro Medicines and its T‑cell engager OM336, planning to split the deal with long‑time partner Galapagos. Johnson & Johnson and Protagonist Therapeutics secured FDA approval for Icotyde, an IL‑23 receptor blocker that becomes Protagonist’s...
Trace Unites ALS Teams Behind a Target That Could Broaden Treatment Access
Trace Neuroscience, launched Nov 2024, is developing an antisense drug, TRCN‑1023, to restore UNC13A protein function in ALS patients. The target emerged from parallel discoveries at UCL and Stanford, and the company plans intrathecal delivery and biomarker‑guided trials. Leveraging lessons...
Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns
Aardvark Therapeutics has paused two Phase 2 obesity trials, POWER and STRENGTH, after cardiac safety signals emerged in its lead compounds ARD‑101 and ARD‑201. The anomalies were observed in healthy volunteers receiving double the target dose, prompting a halt to the...
Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club
Gilead Sciences announced that CEO Daniel O’Day earned $28.44 million in 2025, a 20% increase from the prior year and 119 times the median employee salary. The compensation surge was driven largely by stock awards and incentives. In the same period,...
Japan's Drug Prices Are Creating Problems for Washington and Tokyo Alike
President Donald Trump and Japanese Prime Minister Sanae Takaichi discussed a $40 billion U.S. nuclear investment and pledged cooperation on drug‑pricing reform. Japan plans a 4% cut to total drug spending, further lowering reimbursements for new medicines. The article warns that...
Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite
Kevin Tang, chair of Aurinia’s board and head of Tang Capital Management, has seized the CEO role, replacing Peter Greenleaf, and installed fellow Tang Capital executives as COO, CFO, and CSO. Tang Capital expanded its ownership from 5.1% in September 2024 to 9.2%...
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity investing has shifted from hype to data‑driven strategies, according to LongeVC partners Sergey Jakimov and Artem Trotsyuk. They argue that startups must focus on measurable, disease‑specific mechanisms rather than treating aging as a single target, aligning with FDA and...
Powering the Next Wave of Cell Therapy: From iPSC-Derived Cells to In Vivo Reprogramming
Induced pluripotent stem cells (iPSCs) are being engineered into diverse therapeutic cell types, while in vivo reprogramming aims to convert resident cells directly within patients, eliminating traditional cell‑manufacturing steps. Both strategies depend on precise recombinant growth factors, cytokines, extracellular matrix proteins...
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
Gene‑therapy candidates for hereditary hearing loss are gaining traction as safety concerns ease with localized delivery. Regeneron’s DB‑OTO and Eli Lilly’s AK‑OTOF have each demonstrated clinically meaningful hearing improvements in early‑stage trials, positioning them as frontrunners for the first approved deafness...
9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty
The FDA’s National Priority Voucher (CNPV) program, launched in June 2025, promises to cut drug review times from 10‑12 months to just one or two months for products that meet defined national priorities. Early successes include Johnson & Johnson’s Tecvayli/Darzalex...
Biopharma Could Provide a Haven for Investment as Middle East Conflict Roils Global Markets
Analysts at Truist Securities argue that biopharma has acted as a defensive haven during recent geopolitical turmoil, outperforming the broader S&P 500. Their review of the past six years shows the Health Care Select Sector ETF (XLV) delivering steadier returns and...
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
Sarepta Therapeutics will submit a supplemental NDA to the FDA seeking to convert the accelerated approvals of its Duchenne exon‑skippers Amondys 45 and Vyondys 53 into traditional approvals, despite the confirmatory ESSENCE trial failing to improve motor function. The company bolsters its...
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail
Gossamer Bio announced a near‑half workforce reduction after its Phase 3 seralutinib trial failed to meet statistical significance in pulmonary arterial hypertension. The company will lay off 77 employees, about 48 % of staff, aiming to preserve cash while its future path...
TerraPower Commits $450M to Build Radioisotope Production Plant
TerraPower Isotopes is committing $450 million to build a cGMP‑compliant actinium‑225 manufacturing plant in Philadelphia, a move that will expand production capacity roughly twenty‑fold. The 250,000‑square‑foot facility, slated to begin output in 2029, will create 225 full‑time jobs and benefits from...
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Protagonist Therapeutics received FDA approval for icotrokinra, marketed as Icotyde, becoming the first oral IL‑23 receptor blocker for plaque psoriasis. The clearance arrived ahead of schedule, unlocking a $50 million milestone from Johnson & Johnson and setting up royalty terms of 6‑10% on...
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Structure Therapeutics reported a 16.3% weight loss after 44 weeks in a Phase 2 trial of its oral GLP‑1 pill, positioning it as a competitive alternative to Eli Lilly’s and Novo Nordisk’s candidates. Rhythm Pharmaceuticals disclosed that its obesity drug Imcivree failed in...
Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers
Excalipoint Therapeutics, a Shanghai‑based biotech, closed a $68.7 million seed round, including a $41 million founding raise and a $27.7 million extension led by MPCi, Centurium Capital, Lilly Asia Ventures, and Eisai Innovation. The capital will fund six tri‑specific T‑cell engager candidates, notably...
Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium
The Drug Information Association (DIA) has launched a public‑private AI Consortium that unites regulators, biopharma, academia, and technology firms to shape AI governance in drug development. The group is developing a seven‑step classification framework that aligns AI use‑cases with risk‑proportionate...
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting
The FDA issued a third complete response letter rejecting Aldeyra Therapeutics' lead dry‑eye candidate, reproxalap, citing a lack of substantial evidence and inconsistent efficacy data. The agency noted the drug failed to demonstrate clear benefit in well‑controlled studies, though no...
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection
REGENXBIO's gene therapy RGX‑121 for Hunter syndrome received an FDA Complete Response Letter, with the agency flagging patient‑eligibility definitions, natural‑history control comparability, and the surrogate endpoint as problematic. The rejection redirects focus to Denali Therapeutics, whose enzyme‑replacement candidate tividenofusp alfa...
Biotechs Report Regulatory Headaches, High-Stakes Catalysts During Q4 Earnings
Q4 earnings highlighted a mixed biotech landscape, with regulatory turbulence easing for some firms while high‑stakes catalysts loom. Capricor Therapeutics is preparing to resubmit its Duchenne cardiomyopathy cell therapy after the departure of FDA CBER director Vinay Prasad, and reported...
Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate
Orphan‑drug sales are projected to exceed $400 billion by 2032, more than double the 2025 level. Small‑molecule therapies dominate the pipeline, accounting for 45% of the 20 most valuable orphan candidates, signaling a resurgence after years of biologic focus. The Inflation...
Novo Holdings’ Assets Fell 34% in 2025 As Its Namesake Drugmaker Struggled
Novo Holdings' assets under management plunged 34% in 2025, falling to €93 billion as its controlling stake in Novo Nordisk lost market value. Despite the valuation hit, the holdings generated €2.8 billion in income and delivered 8‑9% five‑ and ten‑year returns, outpacing...
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
BridgeBio Pharma reported that its small‑molecule candidate BBP‑418 produced a 1.8‑fold increase in the α‑dystroglycan biomarker in a Phase 3 FORTIFY trial for limb‑girdle muscular dystrophy type 2I/R9, with effects sustained through 12 months. The trial enrolled 81 patients and also showed...
From Two Trials to One, Sponsors Face a Higher Standard
The FDA announced that a single pivotal trial can now satisfy efficacy requirements for new drug applications, replacing the previous two‑study mandate. This change raises expectations for data depth, quality, and risk‑based management throughout the trial lifecycle. Guests Oxana Iliach...
The Next Cambridge? LA Sets Its Sights Higher
Los Angeles County now hosts more than 3,000 life‑science companies, outpacing peer regions, and generated roughly $58 billion in annual economic output. Venture‑capital inflows surged to $4.4 billion in 2024, a 119 % jump, underscoring growing investor confidence. The ecosystem benefits from a...
Hiring Outlook: February Brings First YOY Job Increase Since 2022
Biopharma job postings on BioSpace rose 5% year‑over‑year in February, the first increase since September 2022, and jumped 21% month‑over‑month. The broader U.S. labor market shed 92,000 jobs, driven by healthcare strikes and winter storms, but biopharma layoffs eased, with...
6 Companies Hiring in Cambridge
Cambridge, Massachusetts remains a premier life‑sciences hub, anchored by giants like Intellia Therapeutics and Moderna and supported by the MassBio trade group. While BioSpace job postings fell 4% year‑over‑year in February, they surged 17% month‑over‑month, reflecting renewed hiring momentum. Six...
Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
Capricor Therapeutics announced that the FDA has scheduled an August 22 decision on its investigational Duchenne muscular dystrophy cell therapy, deramiocel, after lifting a prior complete response letter. The biotech resubmitted an enhanced package that includes robust Phase III HOPE‑3 data showing...
Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles
Big pharma is intensifying its M&A hunt as the pool of late‑stage biopharma assets shrinks, turning deal processes into competitive auctions. Sellers are leveraging multiple inquiries to secure higher upfront cash and better terms, while unsolicited public bids—exemplified by the...
FDA Sets Scope for Attempt To Reduce Manufacturing-Related Approval Rejections
The FDA has defined the scope of pre‑submission facility meetings to curb manufacturing‑related complete response letters that delay drug approvals. It agreed to cover prior production‑site inspections, novel process elements and supply‑chain node strategies, while rejecting topics such as alternative...
AI-Focused Fund Breakout Raises $114M To Support Early-Stage Biotechs
Breakout Ventures announced the close of its third fund, raising $114 million to back AI‑driven biotech startups. The capital will be deployed to early‑stage companies, including a University of Chicago spin‑out focused on computational small‑molecule design and a stealth venture tackling...
Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead
Stylus Medicine entered the cell‑therapy arena in May 2025 with an in‑vivo CAR‑T platform that delivers a lipid nanoparticle‑encapsulated recombinase to engineer T cells inside patients. The move comes after major pharma acquisitions—BMS buying Orbital Therapeutics for $1.5 billion and Gilead...
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
Dyne Therapeutics reported that its exon‑skipping candidate z‑rostudirsen sustained respiratory and cardiac benefits through 24 months in the Phase 1/2 DELIVER study for Duchenne muscular dystrophy. The therapy maintained forced vital capacity, circumferential strain and left‑ventricular ejection fraction improvements compared with...
Single Pivotal Trials Demand Stronger Data and Risk Strategies
Following the FDA’s recent shift to require only one pivotal trial for new drug applications, sponsors now face heightened pressure to generate robust efficacy and safety data. Regulators expect a single, bullet‑proof study rather than two less conclusive trials, mirroring...
Nonprofit Aims To Modernize Manufacturing by Clearing Capital Hurdle
A nonprofit, the API Innovation Center (APIIC), is tackling the capital barrier that prevents U.S. drug makers from adopting continuous manufacturing. By pooling state, federal, philanthropic and private funds, APIIC installs equipment at manufacturers at no upfront cost, de‑risking the...
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie announced top‑line Phase 1 multiple ascending‑dose data for its amylin analog ABBV‑295, showing 7.75‑9.79% weight loss after 12 weeks of treatment. The long‑acting compound was administered every other week then monthly, with a favorable tolerability profile and no serious adverse...
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
Regeneron’s Chinese partner Hansoh announced that its dual GLP‑1/GIPR agonist olatorepatide achieved a 19% mean weight loss in a Phase 3 trial of 604 obese or overweight adults, meeting both co‑primary endpoints. The study reported lower gastrointestinal adverse events compared with...
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations
Xenon Pharmaceuticals reported that its Phase 3 X‑TOLE2 trial of azetukalner, a novel Kv7 potassium channel opener, achieved a 53.2% reduction in focal onset seizures at the 25 mg dose, far exceeding expectations and representing the highest placebo‑adjusted efficacy recorded in a...
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
The FDA’s Oncologic Drugs Advisory Committee will convene on April 30 to evaluate AstraZeneca’s oral SERD camizestrant for first‑line HR‑positive, HER2‑negative breast cancer and its AKT inhibitor Truqap for metastatic hormone‑sensitive prostate cancer. Camizestrant’s Phase 3 SERENA‑6 trial reported a 56% reduction...
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
The FDA rejected Incyte’s supplemental application to add non‑small cell lung cancer to Zynyz’s label, citing compliance failures at Novo Nordisk’s Catalent‑owned Indiana manufacturing plant. The agency’s complete response letter pinpointed inspection findings at the site as the sole approvability...
J&J Wins Third National Priority Approval for Multiple Myeloma Combo
Johnson & Johnson’s Tecvayli and Darzalex combination received FDA approval for second‑line multiple myeloma treatment, marking the third drug cleared under the Commissioner’s National Priority Voucher (CNPV) program. The decision was rendered in just 55 days after J&J’s filing, thanks...
Psychedelics Are Placeholders for More Traditional Depression Therapies: Analysts
Psychedelic antidepressants are poised for FDA review this year, driven by strong investor and patient interest. William Blair analysts note that while Johnson & Johnson’s Spravato generated $1.7 billion in 2025 sales, psychedelics are unlikely to capture the entire treatment‑resistant depression market. Companies...
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
Alnylam Pharmaceuticals has signed a deal with Tenaya Therapeutics, providing $10 million upfront and the potential for up to $1.13 billion in milestones to discover up to 15 new genetic targets for heart disease. Tenaya will apply its modality‑agnostic platform to validate...